TTR and amyloidosis: In the NEURO-TTR trial, three cases (3%) of severe thrombocytopenia, including one in association with a fatal intracranial hemorrhage, were observed during therapy with inotersen, an ASO designed to inhibit hepatic production of transthyretin in patients with hereditary transthyretin amyloidosis.